

Subject index

Volume 69 (2006)

- Acyclovir**; Herpes simplex virus; Foscarnet; Resistance; Real-time PCR **69**, 152
- Adaptive immunity**; Hepatitis C virus; Innate immunity; Interferon system; Escape mechanisms **69**, 129
- alpha-v**; Macrophages; HIV-1; Integrins; Macrophage colony-stimulating factor; Anti-HIV agents **69**, 173
- aMPV**; Avian metapneumovirus; RNA interference; siRNA; Phosphoprotein; Post-transcriptional gene silencing **69**, 46
- Angiotensin-converting enzyme 2**; SARS-CoV; Spike protein; Peptide; Vero E6 cells; Pseudovirus **69**, 70
- Anti-HIV agents**; Macrophages; HIV-1; Integrins; alpha-v; Macrophage colony-stimulating factor **69**, 173
- Antiviral activity**; Lactoferrin; Echovirus; N-lobe; Lactoferricin **69**, 98
- Antiviral**; Arenavirus; Tacaribe; Junín; Hemorrhagic fever **69**, 86
- Arenavirus**; Antiviral; Tacaribe; Junín; Hemorrhagic fever **69**, 86
- Artesunate**; Cytomegalovirus; Drug development; Ferrous iron; Combined antiviral therapy **69**, 60
- Avian metapneumovirus**; aMPV; RNA interference; siRNA; Phosphoprotein; Post-transcriptional gene silencing **69**, 46
- Ceramide**; HIV; Fenretinide; Endocytosis **69**, 116
- Chemokine**; Immune evasion; Human cytomegalovirus; Leukocyte adhesion; Chemokine receptor **69**, 124
- Chemokine**; Pneumovirus; Montelukast; Ribavirin; Mice **69**, 53
- Chemokine receptor**; Immune evasion; Human cytomegalovirus; Leukocyte adhesion; Chemokine **69**, 124
- Citrate**; Rotavirus vaccine; RotaTeq®; Formulation; Disaggregation **69**, 107
- Combined antiviral therapy**; Cytomegalovirus; Drug development; Artesunate; Ferrous iron **69**, 60
- Core promoter**; Hepatitis B virus; Mutation; Transcription factors; Hepatitis B e antigen seroconversion **69**, 142
- CpG ODN**; R-848; Innate; TLR; HSV-2; Vaginal **69**, 77
- Cytomegalovirus**; Drug development; Artesunate; Ferrous iron; Combined antiviral therapy **69**, 60
- Disaggregation**; Rotavirus vaccine; RotaTeq®; Formulation; Citrate **69**, 107
- DNA polymerase**; Kaposi's sarcoma-associated herpesvirus; Processivity factor; Small molecule inhibitor screen **69**, 9
- Drug development**; Cytomegalovirus; Artesunate; Ferrous iron; Combined antiviral therapy **69**, 60
- Drug resistance**; HIV-1; Protease; Insertion; Viral replication **69**, 181
- Drug resistance**; RNA interference; HIV-1; M184V; Lamivudine **69**, 1
- Echovirus**; Lactoferrin; N-lobe; Lactoferricin; Antiviral activity **69**, 98
- Endocytosis**; HIV; Ceramide; Fenretinide **69**, 116
- Escape mechanisms**; Hepatitis C virus; Innate immunity; Interferon system; Adaptive immunity **69**, 129
- Fenretinide**; HIV; Ceramide; Endocytosis **69**, 116
- Ferrous iron**; Cytomegalovirus; Drug development; Artesunate; Combined antiviral therapy **69**, 60
- Flavivirus**; Heparan sulfate mimetic; Japanese encephalitis virus; West Nile virus **69**, 31
- Formulation**; Rotavirus vaccine; RotaTeq®; Citrate; Disaggregation **69**, 107
- Foscarnet**; Herpes simplex virus; Acyclovir; Resistance; Real-time PCR **69**, 152
- HCV**; Replicon; NS5B; Polymerase; Inhibitor **69**, 24
- Hemorrhagic fever**; Arenavirus; Antiviral; Tacaribe; Junín **69**, 86
- Heparan sulfate mimetic**; Flavivirus; Japanese encephalitis virus; West Nile virus **69**, 31
- Hepatitis B e antigen seroconversion**; Hepatitis B virus; Core promoter; Mutation; Transcription factors **69**, 142
- Hepatitis B virus**; Core promoter; Mutation; Transcription factors; Hepatitis B e antigen seroconversion **69**, 142

- Hepatitis C virus;** Innate immunity; Interferon system; Adaptive immunity; Escape mechanisms **69, 129**
- Herpes simplex virus;** Acyclovir; Foscarnet; Resistance; Real-time PCR **69, 152**
- HIV;** Ceramide; Fenretinide; Endocytosis **69, 116**
- HIV-1;** Macrophages; Integrins; alpha-v; Macrophage colony-stimulating factor; Anti-HIV agents **69, 173**
- HIV-1;** Protease; Insertion; Drug resistance; Viral replication **69, 181**
- HIV-1;** RNA interference; Drug resistance; M184V; Lamivudine **69, 1**
- HSV-2;** CpG ODN; R-848; Innate; TLR; Vaginal **69, 77**
- Human cytomegalovirus;** Immune evasion; Leukocyte adhesion; Chemokine receptor; Chemokine **69, 124**
- Immune evasion;** Human cytomegalovirus; Leukocyte adhesion; Chemokine receptor; Chemokine **69, 124**
- Immunogenicity;** Vaccinia virus; Mutants; Pathogenicity **69, 158**
- Influenza;** Peramivir; Mouse model; Intramuscular **69, 39**
- Inhibitor;** HCV; Replicon; NS5B; Polymerase **69, 24**
- Innate;** CpG ODN; R-848; TLR; HSV-2; Vaginal **69, 77**
- Innate immunity;** Hepatitis C virus; Interferon system; Adaptive immunity; Escape mechanisms **69, 129**
- Innate immunity;** Liposome; Plasmid DNA; Phlebovirus **69, 165**
- Insertion;** HIV-1; Protease; Drug resistance; Viral replication **69, 181**
- Integrins;** Macrophages; HIV-1; alpha-v; Macrophage colony-stimulating factor; Anti-HIV agents **69, 173**
- Interferon system;** Hepatitis C virus; Innate immunity; Adaptive immunity; Escape mechanisms **69, 129**
- Intramuscular;** Peramivir; Influenza; Mouse model **69, 39**
- Japanese encephalitis virus;** Flavivirus; Heparan sulfate mimetic; West Nile virus **69, 31**
- Junín;** Arenavirus; Antiviral; Tacaribe; Hemorrhagic fever **69, 86**
- Kaposi's sarcoma-associated herpesvirus;** DNA polymerase; Processivity factor; Small molecule inhibitor screen **69, 9**
- Lactoferricin;** Lactoferrin; Echovirus; N-lobe; Antiviral activity **69, 98**
- Lactoferrin;** Echovirus; N-lobe; Lactoferricin; Antiviral activity **69, 98**
- Lamivudine;** RNA interference; HIV-1; Drug resistance; M184V **69, 1**
- Leukocyte adhesion;** Immune evasion; Human cytomegalovirus; Chemokine receptor; Chemokine **69, 124**
- Liposome;** Plasmid DNA; Innate immunity; Phlebovirus **69, 165**
- M184V;** RNA interference; HIV-1; Drug resistance; Lamivudine **69, 1**
- Macrophage colony-stimulating factor;** Macrophages; HIV-1; Integrins; alpha-v; Anti-HIV agents **69, 173**
- Macrophages;** HIV-1; Integrins; alpha-v; Macrophage colony-stimulating factor; Anti-HIV agents **69, 173**
- Mice;** Pneumovirus; Chemokine; Montelukast; Ribavirin **69, 53**
- Montelukast;** Pneumovirus; Chemokine; Ribavirin; Mice **69, 53**
- Mouse model;** Peramivir; Influenza; Intramuscular **69, 39**
- Mutants;** Vaccinia virus; Pathogenicity; Immunogenicity **69, 158**
- Mutation;** Hepatitis B virus; Core promoter; Transcription factors; Hepatitis B e antigen seroconversion **69, 142**
- N-lobe;** Lactoferrin; Echovirus; Lactoferricin; Antiviral activity **69, 98**
- NS5B;** HCV; Replicon; Polymerase; Inhibitor **69, 24**
- Pathogenicity;** Vaccinia virus; Mutants; Immunogenicity **69, 158**
- Peptide;** SARS-CoV; Spike protein; Angiotensin-converting enzyme 2; Vero E6 cells; Pseudovirus **69, 70**
- Peramivir;** Influenza; Mouse model; Intramuscular **69, 39**
- Phlebovirus;** Liposome; Plasmid DNA; Innate immunity **69, 165**
- Phosphoprotein;** Avian metapneumovirus; aMPV; RNA interference; siRNA; Post-transcriptional gene silencing **69, 46**
- Plasmid DNA;** Liposome; Innate immunity; Phlebovirus **69, 165**
- Pneumovirus;** Chemokine; Montelukast; Ribavirin; Mice **69, 53**
- Polymerase;** HCV; Replicon; NS5B; Inhibitor **69, 24**
- Post-transcriptional gene silencing;** Avian metapneumovirus; aMPV; RNA interference; siRNA; Phosphoprotein **69, 46**
- Processivity factor;** Kaposi's sarcoma-associated herpesvirus; DNA polymerase; Small molecule inhibitor screen **69, 9**
- Protease;** HIV-1; Insertion; Drug resistance; Viral replication **69, 181**
- Pseudovirus;** SARS-CoV; Spike protein; Angiotensin-converting enzyme 2; Peptide; Vero E6 cells **69, 70**
- R-848;** CpG ODN; Innate; TLR; HSV-2; Vaginal **69, 77**
- Real-time PCR;** Herpes simplex virus; Acyclovir; Foscarnet; Resistance **69, 152**
- Replicon;** HCV; NS5B; Polymerase; Inhibitor **69, 24**
- Resistance;** Herpes simplex virus; Acyclovir; Foscarnet; Real-time PCR **69, 152**
- Ribavirin;** Pneumovirus; Chemokine; Montelukast; Mice **69, 53**
- RNA interference;** Avian metapneumovirus; aMPV; siRNA; Phosphoprotein; Post-transcriptional gene silencing **69, 46**
- RNA interference;** HIV-1; Drug resistance; M184V; Lamivudine **69, 1**
- RotaTeq®;** Rotavirus vaccine; Formulation; Citrate; Disaggregation **69, 107**

Rotavirus vaccine; RotaTeq[®]; Formulation; Citrate; Disaggregation **69**, 107

SARS-CoV; Spike protein; Angiotensin-converting enzyme 2; Peptide; Vero E6 cells; Pseudovirus **69**, 70

siRNA; Avian metapneumovirus; aMPV; RNA interference; Phosphoprotein; Post-transcriptional gene silencing **69**, 46

Small molecule inhibitor screen; Kaposi's sarcoma-associated herpesvirus; DNA polymerase; Processivity factor **69**, 9

Spike protein; SARS-CoV; Angiotensin-converting enzyme 2; Peptide; Vero E6 cells; Pseudovirus **69**, 70

Tacaribe; Arenavirus; Antiviral; Junín; Hemorrhagic fever **69**, 86

TLR; CpG ODN; R-848; Innate; HSV-2; Vaginal **69**, 77

Transcription factors; Hepatitis B virus; Core promoter; Mutation; Hepatitis B e antigen seroconversion **69**, 142

Vaccinia virus; Mutants; Pathogenicity; Immunogenicity **69**, 158

Vaginal; CpG ODN; R-848; Innate; TLR; HSV-2 **69**, 77

Vero E6 cells; SARS-CoV; Spike protein; Angiotensin-converting enzyme 2; Peptide; Pseudovirus **69**, 70

Viral replication; HIV-1; Protease; Insertion; Drug resistance **69**, 181

West Nile virus; Flavivirus; Heparan sulfate mimetic; Japanese encephalitis virus **69**, 31